|
Acute Promyelocytic Leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing: BRAF V600E for vemurafenib in melanoma; EML4-ALK for crizotinib and EGFR for erlotinib and gefitinib in non-small-cell lung cancer; KRAS against the use of cetuximab and panitumumab in colorectal cancer; ERBB2 (HER2/neu) for trastuzumab in breast cancer; BCR-ABL for tyrosine kinase inhibitors in chronic myeloid leukemia; and PML/RARα for all-trans-retinoic acid and arsenic trioxide treatment for acute promyelocytic leukemia.
|
22845480 |
2012 |
|
Adenocarcinoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
Moreover, a 47-year-old female with a recurrent adenocarcinoma and a BRAF V600E mutation exhibited tumor regression after a fourth line therapy with dabrafenib and trametinib, targeting agents against BRAF mutations.
|
31440061 |
2019 |
|
Adenocarcinoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
Adenocarcinomas with this clinicopathologic phenotype may be worthwhile investigating for BRAF-V600E mutation as more genetically oriented drug therapies emerge.
|
18636014 |
2008 |
|
Adenocarcinoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
In exon 15, one BRAF mutation (1796 thymine to adenine; V599E) was found in nonsmoking woman with well-differentiated adenocarcinoma.
|
16376942 |
2006 |
|
Adenocarcinoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
Twenty-one BRAF mutations were identified in 951 patients with adenocarcinomas (2.2%; 95% confidence interval [CI], 1.4%-3.4%): 17 (81%; 95% CI, 60%-92%) were BRAF(V600E) mutations, and 4 were non-BRAF(V600E) mutations.
|
25273224 |
2015 |
|
Adenocarcinoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
Lung ADCA harbouring BRAF mutations are commonly non-V600E.
|
30591192 |
2019 |
|
Adenocarcinoma of large intestine
|
|
0.010 |
GeneticVariation
|
BEFREE |
Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.
|
23763264 |
2013 |
|
Adenocarcinoma of lung (disorder)
|
|
0.060 |
GeneticVariation
|
BEFREE |
Among the 204 lung ADCs tested, 11 cases (5.4%) carried HER2 exon 20 insertions and 4 cases (2.0%) had BRAF V600E mutation.
|
26102513 |
2015 |
|
Adenocarcinoma of lung (disorder)
|
|
0.060 |
GeneticVariation
|
BEFREE |
This study compared the specificity and sensitivity of IHC with other methods for the detection of BRAF(V600E) in primary lung adenocarcinoma.
|
23131393 |
2013 |
|
Adenocarcinoma of lung (disorder)
|
|
0.060 |
GeneticVariation
|
BEFREE |
The histopathology of BRAF-V600E-mutated lung adenocarcinoma.
|
18636014 |
2008 |
|
Adenocarcinoma of lung (disorder)
|
|
0.060 |
GeneticVariation
|
BEFREE |
IHC using the VE1 clone and FLEX linker is a specific method for the detection BRAF V600E and may be an alternative to molecular biology for the detection of mutations in lung adenocarcinomas.
|
23927882 |
2013 |
|
Adenocarcinoma of lung (disorder)
|
|
0.060 |
GeneticVariation
|
BEFREE |
Further, the optimal therapeutic strategy to block non-V600E BRAF-mutant LA remains unclear.
|
27834212 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
|
0.060 |
GeneticVariation
|
BEFREE |
The advent of effective targeted therapy for BRAF(V600E) -mutant lung adenocarcinomas necessitates further exploration of the unique clinical features and behavior of advanced-stage BRAF-mutant lung adenocarcinomas.
|
25273224 |
2015 |
|
Advanced Melanoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
PLX4032 is commonly used in the treatment of advanced melanoma patients with BRAF-V600E mutation.
|
31810919 |
2019 |
|
Ameloblastoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
That this therapy was not effective in another primary cell culture led to the discovery of the oncogenic BRAF V600E mutation in a high proportion (63%) of ameloblastoma samples.
|
24749150 |
2014 |
|
Ameloblastoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Our findings suggest an association of BRAF-V600E with parameters of a more aggressive behaviour of ameloblastoma, supporting the future use of BRAF inhibitors for targeted therapy of this neoplasm.
|
27681305 |
2017 |
|
Ameloblastoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
High frequency of BRAF V600E mutations in ameloblastoma.
|
24374844 |
2014 |
|
Anaplastic thyroid carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
The (V600E) BRAF mutation was observed in three ATCs; the results about the inhibition of proliferation by CLM29 and CLM24, obtained in ATC from tumors with (V600E) BRAF mutation were similar to those from tumors without BRAF mutation.
|
26286966 |
2016 |
|
Anaplastic thyroid carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutations were identified in 22.2% of the carcinoma cases (n = 18, 15 PTCs and 3 anaplastic thyroid carcinomas).
|
23746767 |
2013 |
|
Brain Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
PKM2-regulated MLC2 phosphorylation, which is greatly enhanced by EGF stimulation or EGFRvIII, K-Ras G12V and B-Raf V600E mutant expression, plays a pivotal role in cytokinesis, cell proliferation and brain tumour development.
|
25412762 |
2014 |
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing: BRAF V600E for vemurafenib in melanoma; EML4-ALK for crizotinib and EGFR for erlotinib and gefitinib in non-small-cell lung cancer; KRAS against the use of cetuximab and panitumumab in colorectal cancer; ERBB2 (HER2/neu) for trastuzumab in breast cancer; BCR-ABL for tyrosine kinase inhibitors in chronic myeloid leukemia; and PML/RARα for all-trans-retinoic acid and arsenic trioxide treatment for acute promyelocytic leukemia.
|
22845480 |
2012 |
|
BRONCHIAL ADENOCARCINOMA
|
|
0.010 |
GeneticVariation
|
BEFREE |
Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.
|
25466451 |
2015 |
|
Carcinoma of lung
|
|
0.050 |
GeneticVariation
|
BEFREE |
Accordingly, the combination of MEK inhibitor with EGFR inhibitor was effective at shrinking tumors in mouse model of BRAF non-V600E mutant lung cancer.
|
29348459 |
2018 |
|
Carcinoma of lung
|
|
0.050 |
GeneticVariation
|
BEFREE |
V599E BRAF mutation was uncommon in Japanese lung cancer.
|
16376942 |
2006 |
|
Carcinoma of lung
|
|
0.050 |
GeneticVariation
|
BEFREE |
The Lung Cancer Mutation Consortium (LCMC) is a multi-institutional effort to identify and treat oncogenic driver events in patients with lung adenocarcinomas.<b>Experimental Design:</b> Sixteen U.S. institutions enrolled 1,367 patients with lung cancer in LCMC2; 904 were deemed eligible and had at least one of 14 cancer-related genes profiled using validated methods including genotyping, massively parallel sequencing, and IHC.<b>Results:</b> The use of targeted therapies in patients with <i>EGFR, ERBB2,</i> or <i>BRAF</i> p.V600E mutations, <i>ALK, ROS1</i>, or <i>RET</i> rearrangements, or <i>MET</i> amplification was associated with a survival increment of 1.5 years compared with those with such mutations not receiving targeted therapy, and 1.0 year compared with those lacking a targetable driver.
|
29217530 |
2018 |